Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agilent looks fundamentally undervalued after losing 30% since its ATH. The company delivers consistently solid financial results and is forecasted to further increase its profitability.

Agilent: A Strong Leader With Great Opportunities

AMETEK

Cognex

Fortive

Coronavirus--led disruptions are hurting the Zacks Electronics - Testing Equipment industry. However, industry participants like A, AME, FTV and CGNX are set to gain from 5G prospects.

4 Testing Equipment Stocks to Escape a Challenging Industry

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced cancer research innovations in cell analysis and genomics that will be on show at the American Association for Cancer Research Annual Meeting, being held April 8 - 13, 2022 in New Orleans, Louisiana. “Cancer research is an important focus area for Agilent. The AACR conference presents an exciting opportunity to engage with customers, partners, and thought leaders in this field,” said Jodi Barrientos, vice

Agilent Highlights Genomics and Cell Analysis Solutions for Cancer Research at AACR 2022

Agilent Technologies (A) boosts its presence in the companion diagnostics market by expanding the use of PD-L1 IHC 28-8 pharmDx assay for esophageal squamous cell carcinoma treatment in the EU.

Agilent (A) Boosts PD-L1 IHC 28-8 pharmDX Use in European Union

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay to extend the use of the test to patients diagnosed with muscle-invasive urothelial carcinoma (MIUC) who have tumor cell PD-L1 expression ≥ 1% for adjuvant treatment with OPDIVO® (nivolumab), a PD-1-targeted immunotherapeutic from Bristol Myers Squibb. Urothelial carcinoma is the 10th most common cancer worldwide,

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has expanded CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx as an aid in identifying esophageal squamous cell carcinoma patients for treatment with Bristol Myers Squibb's PD-1-targeted immunotherapeutic OPDIVO® (nivolumab), in combination with fluoropyrimidine and platinum-based chemotherapy or OPDIVO® in combination with YERVOY® (ipilimumab). These combined treatments provide new h

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it has become a member of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC). Joining AMBIC demonstrates the company's commitment to partnering to support the provision of the next generation of analytical tools and comprehensive solutions needed by academic, pharmaceutical, and clinical researchers. Agilent plays a key role in providing solutions for the analytical needs of customers i

Agilent Joins AMBIC to Advance Biomanufacturing

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Agilent (A) Up 6.5% Since Last Earnings Report: Can It Continue?

Genetron Holdings

SAN DIEGO--(BUSINESS WIRE)-- #3Dgenomics--Arima Genomics closes $7M series B financing to support continued growth of 3D genomics portfolio for research and translational applications.

Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Research and Translational Applications

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the recipient of the 2022 Darlene Solomon Award is Federica Fiorini, Ph.D., a research associate studying metabolomics at the Institute of Biology and Pathology at the Grenoble Alpes University Hospital (CHU Grenoble Alpes) in France. The award was presented at the iSLS10–10th International Singapore Lipid Symposium held March 8–10 at the National University of Singapore. “I am extremely honored and e

Agilent Announces the 2022 Darlene Solomon Award Presented to Grenoble Alpes University Hospital Scientist Dr. Federica Fiorini

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #agilent--Agilent Technologies Inc. (NYSE: A) today announced that Bob McMahon, senior vice president and chief financial officer, will participate in Q&A sessions at the Cowen 42nd Annual Health Care Conference and the Barclays Global Health Care Conference. Below are the details: Cowen 42nd Annual Health Care Conference Tuesday, March 8, 2022 11:10 a.m. EST / 8:10 a.m. PST Barclays Global Health Care Conference Wednesday, March 16, 2022 2:05 p.m. EDT / 11:05 a.

Agilent to Participate at Cowen and Barclays Health Care Conferences

Agilent (A) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 5.6% in 4 Weeks, Here's Why Agilent (A) Looks Ripe for a Turnaround

SANTA CLARA, Calif. & BURLINGTON, Vt.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) and the University of Vermont (UVM) today announced the establishment of the Agilent Laboratory for Chemical Analysis (ALCA). The facility will be a hub for advanced instrumentation that will allow students, institutional colleagues, industrial partners, and regional high-tech start-ups to study the composition and structure of chemical samples. It is intended as a shared educational and research space t

Agilent and University of Vermont Announce the Agilent Laboratory for Chemical Analysis (ALCA)

Agilent's (A) fiscal first-quarter results benefit from solid momentum across all operating segments. Further, strong growth in the pharma market remains a tailwind.

Agilent (A) Q1 Earnings & Revenues Beat Estimates, Rise Y/Y

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that researchers from the QIMR Berghofer Medical Research Institute in Brisbane, Australia, collaborated with Agilent experts on a proof-of-concept FTIR-based saliva COVID-19 testing workflow using the Agilent Cary 630 FTIR Spectrometer. The study investigated the pathophysiological response to a COVID-19 infection through ATR-FTIR spectroscopy. The researchers acquired infrared spectra of saliva samples f

Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening

Agilent Technologies, Inc.'s (A) CEO Mike McMullen on Q1 2022 Results - Earnings Call Transcript

Agilent (A) delivered earnings and revenue surprises of 3.42% and 1.30%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Agilent Technologies (A) Q1 Earnings and Revenues Beat Estimates

Shares of Agilent Technologies Inc. A, -1.18% initially were initially up 1% in extended trading Tuesday after the company reported fiscal first-quarter results that were slightly above Wall Street analysts' forecasts. Agilent posted net income of $283 million, or 93 cents a share, compared with net income of $288 million, or 93 cents a share, in the year-ago quarter.

Agilent Technologies shares up 1% after it reports better-than-expected results

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the first quarter ended Jan. 31, 2022, an increase of 8% compared to the first quarter of 2021 and up 9% on a core(1) basis. On a GAAP basis, first-quarter net income was $283 million, or $0.93 per share. This compares with $288 million, or $0.93 per share, in the first quarter of fiscal year 2021. Non-GAAP(2) net income was $368 million, or $1.21 per share during the quarter, c

Agilent Reports First-Quarter Fiscal Year 2022 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent Technologies Inc. (NYSE: A) today announced it has acquired advanced artificial intelligence (AI) technology developed by Virtual Control, an AI and machine learning software developer that creates innovative analysis solutions in lab testing. Agilent will integrate the software, known as ACIES, into its industry-leading gas chromatography and mass spectrometry (GS/MS) platforms to improve the productivity, efficiency and accuracy of high-throughput

Agilent Acquires Artificial Intelligence Technology to Enhance Lab Productivity

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) highlights innovative laboratory automation solutions at the SLAS2022 International Conference and Exhibition held February 5 through February 9, 2022, at the Boston Convention and Exhibition Center in Boston, Massachusetts. Agilent modular automation solutions address a wide array of cell analysis, mass spectrometry, and genomics workflows in both development and regulated environments. Overall, sample preparation is mor

Agilent Highlights Integrated Automation Solutions at SLAS 2022

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the Singapore Institute of Food and Biotechnology Innovation (SIFBI) outlining their collaboration on developing food research knowledge advancement over the next two years. SIFBI is a research institute under the Agency for Science, Technology, and Research (A*STAR) in Singapore. This collaboration aims to bring state-of-the-art science and technology to drive

Agilent and A*STAR's SIFBI Sign Research Collaboration Agreement to Advance Singapore Agri-Food Industry

Agilent (A) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Agilent (A) Could be Great Choice for a Bottom Fisher

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools. With enhanced performance, more robust and efficient workflows, and an optimized user experience, the XF Pro enables operators at any skill level to access the most advanced cellular metabolism analysis technology for understanding cellular fat

Agilent Announces the Innovative Seahorse XF Pro Analyzer

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent Technologies Inc. (NYSE: A) will release first-quarter fiscal year 2022 financial results after the stock market closes on Tuesday, Feb. 22. The company will host a live webcast of its investor conference call in listen-only mode on the same day. Details for the webcast: Date: Tuesday, Feb. 22, 2022. Time: 1:30 p.m. Pacific time. Web access: Links will be provided in the Upcoming Events section of Agilent's investor relations website. The webcast wi

News for Agilent Technologies Stock (A)